SCHEMBL3073303

SCHEMBL3073303

O=S(=O)(CCc1cccc(OC(F)(F)F)c1)c1ccc(S(=O)(=O)Nc2ncc(F)s2)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 13/20 0.43
SCN5A Q14524 5/20 0.40
SCN8A Q9UQD0 5/20 0.40
SCN1A P35498 4/20 0.40
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
FBP1 P09467 1/20 0.39
SCN3A Q9NY46 3/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
MMP14 P50281 1/20 0.38
ADAM17 P78536 1/20 0.38
NR1I2 O75469 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
SCN2A Q99250 2/20 0.36
SCN10A Q9Y5Y9 2/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3056832 0.92 SCN9A (0.42) SCN9ASCN5ASCN8ASCN1AFBP1
SCHEMBL3073762 0.90 SCN3A (0.44) SCN9ACHRM2CHRM1CHRM3FBP1
SCHEMBL3066556 0.87 SCN9A (0.45) SCN9ASCN5ASCN8ASCN1ASCN3A
SCHEMBL3050851 0.86 SCN3A (0.53) SCN9ASCN5ASCN8ASCN1ASCN3A
SCHEMBL3069388 0.83 SCN9A (0.48) SCN9ASCN3A
SCHEMBL3064960 0.81 SCN9A (0.44) SCN9ACHRM2CHRM1CHRM3FBP1
SCHEMBL3063584 0.80 SCN9A (0.46) SCN9ASCN5ASCN1ACHRM2CHRM1
SCHEMBL3071424 0.78 SCN9A (0.42) SCN9ASCN5ASCN8ASCN1ASCN3A
SCHEMBL3064189 0.78 SCN3A (0.46) SCN9ASCN1ASCN3ASCN2ASCN10A
SCHEMBL3066154 0.78 SCN9A (0.47) SCN9ASCN1ASCN3ASCN2ASCN10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140357685-A1 Sodium Channel Inhibitors ICAGEN INC (US) 2014-12-04 US disclosed
US-8853250-B2 Sodium channel inhibitors ICAGEN, INC. (US) 2014-10-07 US disclosed
EP-2175728-B1 SODIUM CHANNEL INHIBITORS ICAGEN INC (US) 2014-09-10 EP disclosed
US-20100267782-A1 SODIUM CHANNEL INHIBITORS ICAGEN, INC (US) 2010-10-21 US disclosed
EP-2175728-A1 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-21 EP disclosed
WO-2009012241-A1 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357685-A1 Sodium Channel Inhibitors TRPV1, SCN1A, SCN2A SCN9A 19/4885SCN5A 7/4885SCN8A 44/4885
US-20100267782-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A SCN9A 19/4885SCN5A 7/4885SCN8A 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.